Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial
Authors:
Open Access
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 51 (2) , 469-476
Abstract
No abstract availableKeywords
Funding Information
- Genentech Inc
This publication has 23 references indexed in Scilit:
- Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet, 2016
- Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable casesRMD Open, 2015
- 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiativeAnnals of the Rheumatic Diseases, 2015
- Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort StudyThe Journal of Rheumatology, 2015
- Large-vessel giant cell arteritis: a cohort studyRheumatology, 2014
- Relapses in Patients With Giant Cell ArteritisMedicine, 2014
- Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapyClinical Rheumatology, 2014
- The diagnosis and classification of giant cell arteritisJournal of Autoimmunity, 2014
- Polymyalgia rheumatica and giant-cell arteritisThe Lancet, 2008
- Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomesArthritis Care & Research, 2003